DE GIORGI, UGO FEDERICO FRANCESCO
DE GIORGI, UGO FEDERICO FRANCESCO
DIPARTIMENTO DI MEDICINA SPERIMENTALE
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers
2024-01-01 Giunta, Emilio Francesco; Brighi, Nicole; Gurioli, Giorgia; Matteucci, Federica; Paganelli, Giovanni; De Giorgi, Ugo
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases
2010-01-01 De Giorgi, U; Mego, M; Rohren, E; Liu, P; Handy, Bc; Reuben, Jm; Macapinlac, Ha; Hortobagyi, Gn; Cristofanilli, M; Ueno, Nt.
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
2015-01-01 De Giorgi, U; Caroli, P; Scarpi, E; Conteduca, V; Burgio, Sl; Menna, C; Moretti, A; Galassi, R; Rossi, L; Amadori, D; Paganelli, G; Matteucci, F
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
2015-01-01 DE GIORGI, Ugo; Caroli, Paola; Scarpi, Emanuela; Conteduca, Vincenza; Burgio, Salvatore Luca; Menna, Cecilia; Moretti, Andrea; Galassi, Riccardo; Rossi, Lorena; Amadori, Dino; Paganelli, Giovanni; Matteucci, Federica
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients
2018-01-01 Caroli, Paola; Sandler, Israel; Matteucci, Federica; de Giorgi, Ugo; Uccelli, Licia; Celli, Monica; Foca, Flavia; Barone, Domenico; Romeo, Antonino; Sarnelli, Anna; Paganelli, Giovanni
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer
2018-01-01 Malaspina, Simona; De Giorgi, Ugo; Kemppainen, Jukka; Del Sole, Angelo; Paganelli, Giovanni
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?
2018-01-01 Paganelli, Giovanni; De Giorgi, Ugo
[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.
2010-01-01 De Giorgi, U; Amadori, D.
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity
2001-01-01 Bacci, G; Ferrari, S; Tienghi, A; Bertoni, F; Mercuri, M; Longhi, A; Fiorentini, G; Forni, C; Bacchini, P; Rimondini, S; De Giorgi, U; Picci, P
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma
2020-01-01 Lolli, C.; Altavilla, A.; Conteduca, V.; Farolfi, A.; Casadei, C.; Schepisi, G.; Banna, G. L.; De Giorgi, U.
A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
2023-01-01 Fernandez‐perez, María P.; Perez‐navarro, Enrique; Alonso‐gordoa, Teresa; Conteduca, Vicenza; Font, Albert; Vázquez‐estévez, Sergio; González‐del‐alba, Aránzazu; Wetterskog, Daniel; Antonarakis, Emmanuel S.; Mellado, Begona; Fernandez‐calvo, Ovidio; Méndez‐vidal, María J.; Climent, Miguel A.; Duran, Ignacio; Gallardo, Enrique; Rodriguez Sanchez, Angel; Santander, Carmen; Sáez, Maria I.; Puente, Javier; Tudela, Julian; Martínez, Alberto; López‐andreo, Maria J.; Padilla, José; Lozano, Rebeca; Hervas, David; Luo, Jun; De Giorgi, Ugo; Castellano, Daniel; Attard, Gerhardt; Grande, Enrique; Gonzalez‐billalabeitia, Enrique
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group
2022-01-01 Bartoletti, M.; Bergamini, A.; Giannone, G.; Nero, C.; Musacchio, L.; Farolfi, A.; Passarelli, A.; Kuhn, E.; Castaldo, D.; Lombardo, V.; Di Palma, T.; Lorusso, D.; Puglisi, F.; De Giorgi, U.; Valabrega, G.; Schettino, C.; Scambia, G.; Capoluongo, E.; Pignata, S.
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients
2012-01-01 Eechoute, K; Fransson, Mn; Reyners, Ak; de Jong, Fa; Sparreboom, A; van der Graaf, Wt; Friberg, Le; Schiavon, G; Wiemer, Ea; Verweij, J; Loos, Wj; Mathijssen, Rh; De Giorgi, U
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer
2015-01-01 Pietri, E; Andreis, D; Fabbri, F; Menna, C; Schirone, A; Kopf, B; Rocca, A; Amadori, D; De Giorgi, U
A Phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer
2017-01-01 Lolli, C; Gallà, V; Schepisi, G; Barone, D; Luca Burgio, S; Maugeri, A; Vertogen, B; Amadori, D; De Giorgi, U
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
2023-01-01 Cortesi, L.; Venturelli, M.; Cortesi, G.; Caggia, F.; Toss, A.; Barbieri, E.; De Giorgi, U.; Guarneri, V.; Musolino, A.; De Matteis, E.; Zambelli, A.; Bisagni, G.; Dominici, M.
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization
2006-01-01 Kopf, B; De Giorgi, U; Vertogen, B; Monti, G; Molinari, A; Turci, D; Dazzi, C; Leoni, M; Tienghi, A; Cariello, A; Argnani, M; Frassineti, L; Scarpi, E; Rosti, G; Marangolo, M.
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study
2000-01-01 Dazzi, C; Cariello, A; Giannini, M; Del Duca, M; Giovanis, P; Fiorentini, G; Leoni, M; Rosti, G; Turci, D; Tienghi, A; Vertogen, B; Zumaglini, F; De Giorgi, U; Marangolo, M
Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?
2023-01-01 De Giorgi, U.; Giunta, E. F.; Verzoni, E.; Procopio, G.
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
2022-01-01 Maiorano, B. A.; De Giorgi, U.; Roviello, G.; Messina, C.; Altavilla, A.; Cattrini, C.; Mennitto, A.; Maiello, E.; Di Maio, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers | 1-gen-2024 | Giunta, Emilio Francesco; Brighi, Nicole; Gurioli, Giorgia; Matteucci, Federica; Paganelli, Giovanni; De Giorgi, Ugo | |
| 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases | 1-gen-2010 | De Giorgi, U; Mego, M; Rohren, E; Liu, P; Handy, Bc; Reuben, Jm; Macapinlac, Ha; Hortobagyi, Gn; Cristofanilli, M; Ueno, Nt. | |
| 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide | 1-gen-2015 | De Giorgi, U; Caroli, P; Scarpi, E; Conteduca, V; Burgio, Sl; Menna, C; Moretti, A; Galassi, R; Rossi, L; Amadori, D; Paganelli, G; Matteucci, F | |
| 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide | 1-gen-2015 | DE GIORGI, Ugo; Caroli, Paola; Scarpi, Emanuela; Conteduca, Vincenza; Burgio, Salvatore Luca; Menna, Cecilia; Moretti, Andrea; Galassi, Riccardo; Rossi, Lorena; Amadori, Dino; Paganelli, Giovanni; Matteucci, Federica | |
| 68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients | 1-gen-2018 | Caroli, Paola; Sandler, Israel; Matteucci, Federica; de Giorgi, Ugo; Uccelli, Licia; Celli, Monica; Foca, Flavia; Barone, Domenico; Romeo, Antonino; Sarnelli, Anna; Paganelli, Giovanni | |
| 68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer | 1-gen-2018 | Malaspina, Simona; De Giorgi, Ugo; Kemppainen, Jukka; Del Sole, Angelo; Paganelli, Giovanni | |
| [177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? | 1-gen-2018 | Paganelli, Giovanni; De Giorgi, Ugo | |
| [18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. | 1-gen-2010 | De Giorgi, U; Amadori, D. | |
| A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity | 1-gen-2001 | Bacci, G; Ferrari, S; Tienghi, A; Bertoni, F; Mercuri, M; Longhi, A; Fiorentini, G; Forni, C; Bacchini, P; Rimondini, S; De Giorgi, U; Picci, P | |
| A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma | 1-gen-2020 | Lolli, C.; Altavilla, A.; Conteduca, V.; Farolfi, A.; Casadei, C.; Schepisi, G.; Banna, G. L.; De Giorgi, U. | |
| A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide | 1-gen-2023 | Fernandez‐perez, María P.; Perez‐navarro, Enrique; Alonso‐gordoa, Teresa; Conteduca, Vicenza; Font, Albert; Vázquez‐estévez, Sergio; González‐del‐alba, Aránzazu; Wetterskog, Daniel; Antonarakis, Emmanuel S.; Mellado, Begona; Fernandez‐calvo, Ovidio; Méndez‐vidal, María J.; Climent, Miguel A.; Duran, Ignacio; Gallardo, Enrique; Rodriguez Sanchez, Angel; Santander, Carmen; Sáez, Maria I.; Puente, Javier; Tudela, Julian; Martínez, Alberto; López‐andreo, Maria J.; Padilla, José; Lozano, Rebeca; Hervas, David; Luo, Jun; De Giorgi, Ugo; Castellano, Daniel; Attard, Gerhardt; Grande, Enrique; Gonzalez‐billalabeitia, Enrique | |
| A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group | 1-gen-2022 | Bartoletti, M.; Bergamini, A.; Giannone, G.; Nero, C.; Musacchio, L.; Farolfi, A.; Passarelli, A.; Kuhn, E.; Castaldo, D.; Lombardo, V.; Di Palma, T.; Lorusso, D.; Puglisi, F.; De Giorgi, U.; Valabrega, G.; Schettino, C.; Scambia, G.; Capoluongo, E.; Pignata, S. | |
| A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients | 1-gen-2012 | Eechoute, K; Fransson, Mn; Reyners, Ak; de Jong, Fa; Sparreboom, A; van der Graaf, Wt; Friberg, Le; Schiavon, G; Wiemer, Ea; Verweij, J; Loos, Wj; Mathijssen, Rh; De Giorgi, U | |
| A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer | 1-gen-2015 | Pietri, E; Andreis, D; Fabbri, F; Menna, C; Schirone, A; Kopf, B; Rocca, A; Amadori, D; De Giorgi, U | |
| A Phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer | 1-gen-2017 | Lolli, C; Gallà, V; Schepisi, G; Barone, D; Luca Burgio, S; Maugeri, A; Vertogen, B; Amadori, D; De Giorgi, U | |
| A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) | 1-gen-2023 | Cortesi, L.; Venturelli, M.; Cortesi, G.; Caggia, F.; Toss, A.; Barbieri, E.; De Giorgi, U.; Guarneri, V.; Musolino, A.; De Matteis, E.; Zambelli, A.; Bisagni, G.; Dominici, M. | |
| A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization | 1-gen-2006 | Kopf, B; De Giorgi, U; Vertogen, B; Monti, G; Molinari, A; Turci, D; Dazzi, C; Leoni, M; Tienghi, A; Cariello, A; Argnani, M; Frassineti, L; Scarpi, E; Rosti, G; Marangolo, M. | |
| A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study | 1-gen-2000 | Dazzi, C; Cariello, A; Giannini, M; Del Duca, M; Giovanis, P; Fiorentini, G; Leoni, M; Rosti, G; Turci, D; Tienghi, A; Vertogen, B; Zumaglini, F; De Giorgi, U; Marangolo, M | |
| Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing? | 1-gen-2023 | De Giorgi, U.; Giunta, E. F.; Verzoni, E.; Procopio, G. | |
| Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis | 1-gen-2022 | Maiorano, B. A.; De Giorgi, U.; Roviello, G.; Messina, C.; Altavilla, A.; Cattrini, C.; Mennitto, A.; Maiello, E.; Di Maio, M. |